Paid non-client promotion: Affiliate links for the products on this page are from partners that compensate us (see our advertiser disclosure with our list of partners for more details). However, our ...

Each New Year, the financial media praise and blame 12-month results for stocks, mutual funds, bonds and Tony Blair futures. Biotech investors may well pop a few corks, with the AMEX Biotechnology ...

Euronext currently is undervalued and should have above market returns in the years to come. It has a long-term growing dividend and a 10%+ Free Cash Flow Yield. It's a Pan-European leader after ...

LifeVantage (LFVN) is a mispriced opportunity with potential for >15% IRR, driven by its new GLP-1 product suite and turnaround signals. LFVN's valuation is attractive at ~6x EV/EBITDA and a Fwd PEG ...